205 related articles for article (PubMed ID: 18851679)
1. The level of APOBEC3G (hA3G)-related G-to-A mutations does not correlate with viral load in HIV type 1-infected individuals.
Ulenga NK; Sarr AD; Hamel D; Sankale JL; Mboup S; Kanki PJ
AIDS Res Hum Retroviruses; 2008 Oct; 24(10):1285-90. PubMed ID: 18851679
[TBL] [Abstract][Full Text] [Related]
2. Anti-APOBEC3G activity of HIV-1 Vif protein is attenuated in elite controllers.
Kikuchi T; Iwabu Y; Tada T; Kawana-Tachikawa A; Koga M; Hosoya N; Nomura S; Brumme ZL; Jessen H; Pereyra F; Trocha A; Walker BD; Iwamoto A; Tokunaga K; Miura T
J Virol; 2015 May; 89(9):4992-5001. PubMed ID: 25717111
[TBL] [Abstract][Full Text] [Related]
3. Functional analysis of the two cytidine deaminase domains in APOBEC3G.
Li X; Ma J; Zhang Q; Zhou J; Yin X; Zhai C; You X; Yu L; Guo F; Zhao L; Li Z; Zeng Y; Cen S
Virology; 2011 Jun; 414(2):130-6. PubMed ID: 21489586
[TBL] [Abstract][Full Text] [Related]
4. Tumultuous relationship between the human immunodeficiency virus type 1 viral infectivity factor (Vif) and the human APOBEC-3G and APOBEC-3F restriction factors.
Henriet S; Mercenne G; Bernacchi S; Paillart JC; Marquet R
Microbiol Mol Biol Rev; 2009 Jun; 73(2):211-32. PubMed ID: 19487726
[TBL] [Abstract][Full Text] [Related]
5. APOBEC3F and APOBEC3G mRNA levels do not correlate with human immunodeficiency virus type 1 plasma viremia or CD4+ T-cell count.
Cho SJ; Drechsler H; Burke RC; Arens MQ; Powderly W; Davidson NO
J Virol; 2006 Feb; 80(4):2069-72. PubMed ID: 16439564
[TBL] [Abstract][Full Text] [Related]
6. The dimerization domain of HIV-1 viral infectivity factor Vif is required to block virion incorporation of APOBEC3G.
Miller JH; Presnyak V; Smith HC
Retrovirology; 2007 Nov; 4():81. PubMed ID: 18036235
[TBL] [Abstract][Full Text] [Related]
7. APOBEC3G levels predict rates of progression to AIDS.
Jin X; Wu H; Smith H
Retrovirology; 2007 Mar; 4():20. PubMed ID: 17374143
[TBL] [Abstract][Full Text] [Related]
8. Nuclear Exclusion of the HIV-1 host defense factor APOBEC3G requires a novel cytoplasmic retention signal and is not dependent on RNA binding.
Bennett RP; Presnyak V; Wedekind JE; Smith HC
J Biol Chem; 2008 Mar; 283(12):7320-7. PubMed ID: 18165230
[TBL] [Abstract][Full Text] [Related]
9. Function analysis of sequences in human APOBEC3G involved in Vif-mediated degradation.
Zhang L; Saadatmand J; Li X; Guo F; Niu M; Jiang J; Kleiman L; Cen S
Virology; 2008 Jan; 370(1):113-21. PubMed ID: 17916373
[TBL] [Abstract][Full Text] [Related]
10. APOBEC3G-induced hypermutation of human immunodeficiency virus type-1 is typically a discrete "all or nothing" phenomenon.
Armitage AE; Deforche K; Chang CH; Wee E; Kramer B; Welch JJ; Gerstoft J; Fugger L; McMichael A; Rambaut A; Iversen AK
PLoS Genet; 2012; 8(3):e1002550. PubMed ID: 22457633
[TBL] [Abstract][Full Text] [Related]
11. Relationship between human immunodeficiency type 1 infection and expression of human APOBEC3G and APOBEC3F.
Ulenga NK; Sarr AD; Thakore-Meloni S; Sankalé JL; Eisen G; Kanki PJ
J Infect Dis; 2008 Aug; 198(4):486-92. PubMed ID: 18598197
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of tRNA₃(Lys)-primed reverse transcription by human APOBEC3G during human immunodeficiency virus type 1 replication.
Guo F; Cen S; Niu M; Saadatmand J; Kleiman L
J Virol; 2006 Dec; 80(23):11710-22. PubMed ID: 16971427
[TBL] [Abstract][Full Text] [Related]
13. Small molecular compounds inhibit HIV-1 replication through specifically stabilizing APOBEC3G.
Cen S; Peng ZG; Li XY; Li ZR; Ma J; Wang YM; Fan B; You XF; Wang YP; Liu F; Shao RG; Zhao LX; Yu L; Jiang JD
J Biol Chem; 2010 May; 285(22):16546-52. PubMed ID: 20363737
[TBL] [Abstract][Full Text] [Related]
14. Mutational alteration of human immunodeficiency virus type 1 Vif allows for functional interaction with nonhuman primate APOBEC3G.
Schröfelbauer B; Senger T; Manning G; Landau NR
J Virol; 2006 Jun; 80(12):5984-91. PubMed ID: 16731937
[TBL] [Abstract][Full Text] [Related]
15. Resistance of human T cell leukemia virus type 1 to APOBEC3G restriction is mediated by elements in nucleocapsid.
Derse D; Hill SA; Princler G; Lloyd P; Heidecker G
Proc Natl Acad Sci U S A; 2007 Feb; 104(8):2915-20. PubMed ID: 17299050
[TBL] [Abstract][Full Text] [Related]
16. Likely role of APOBEC3G-mediated G-to-A mutations in HIV-1 evolution and drug resistance.
Jern P; Russell RA; Pathak VK; Coffin JM
PLoS Pathog; 2009 Apr; 5(4):e1000367. PubMed ID: 19343218
[TBL] [Abstract][Full Text] [Related]
17. APOBEC3G/CEM15 (hA3G) mRNA levels associate inversely with human immunodeficiency virus viremia.
Jin X; Brooks A; Chen H; Bennett R; Reichman R; Smith H
J Virol; 2005 Sep; 79(17):11513-6. PubMed ID: 16103203
[TBL] [Abstract][Full Text] [Related]
18. Identification of small molecule compounds targeting the interaction of HIV-1 Vif and human APOBEC3G by virtual screening and biological evaluation.
Ma L; Zhang Z; Liu Z; Pan Q; Wang J; Li X; Guo F; Liang C; Hu L; Zhou J; Cen S
Sci Rep; 2018 May; 8(1):8067. PubMed ID: 29795228
[TBL] [Abstract][Full Text] [Related]
19. Human APOBEC3G-mediated hypermutation is associated with antiretroviral therapy failure in HIV-1 subtype C-infected individuals.
Neogi U; Shet A; Sahoo PN; Bontell I; Ekstrand ML; Banerjea AC; Sonnerborg A
J Int AIDS Soc; 2013 Feb; 16(1):18472. PubMed ID: 23443042
[TBL] [Abstract][Full Text] [Related]
20. Possible footprints of APOBEC3F and/or other APOBEC3 deaminases, but not APOBEC3G, on HIV-1 from patients with acute/early and chronic infections.
Armitage AE; Deforche K; Welch JJ; Van Laethem K; Camacho R; Rambaut A; Iversen AK
J Virol; 2014 Nov; 88(21):12882-94. PubMed ID: 25165112
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
